Skip to main content

Gillies Hunter's Form 4 filing

Jade Biosciences, Inc. (JBIO) · filed Apr 19, 2024

Accession no.
0001415889-24-011251
Filed
Apr 19, 2024
Trade date
Apr 17, 2024
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $89.5K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Gillies HunterCIK 0001868997Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 17, 2024Common StockMOption exerciseAcquired+4,000$1.74+$6,9607,251Direct
Apr 17, 2024Common StockSSaleDisposed−3,689$22.30−$82,264.73,562Direct
Apr 17, 2024Common StockSSaleDisposed−311$23.33−$7,255.633,251Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 17, 2024Common StockMOption exerciseDisposed−503$0.00$02,511Direct
Apr 17, 2024Common StockMOption exerciseDisposed−3,497$0.00$0539Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)